EU Exit and UK MVS

The United Kingdom formally departed from the European Union on 31st January 2020, entering into a Transition Period lasting until 31st December 2020.   During the Transition Period the UK continues to remain in the single market and consequently remains fully aligned to EU Law.  This means that the Falsified Medicines Directive (FMD) and associated Delegated Regulation (DR) continues to apply to all in the UK supply chain at least until 31st December 2020, as if the UK were still a member of the EU. 

The United Kingdom comprises of Great Britain and Northern Ireland.  The Great Britain countries are England, Scotland, Wales together with the Crown Dependencies of Isle of Man and Channel Islands.   These are the GB countries

At the end of the Transition Period, the UK becomes a third country in relation to the EU. Unless a negotiated UK/EU trade agreement outcome provides that the EU pharmaceutical regulatory framework applies to the UK, the UK legislation relating to FMD and associated Delegated Regulation will be withdrawn by the UK government as of 1st January 2021.    GB country supply chain stakeholders will no longer be able to consistently comply with the established European Union-wide rules and requirements as a result of FMD/DR being withdrawn.    

This would mean that MAHs based in the EU would need to stop uploading pack data for the UK Medicines Verification System to EMVS as of 1st January 2021, to remain compliant with EU law.  The UK medicines regulator MHRA will provide any official guidance on whether serialisation / serialized packs can still be supplied into the UK after 1st January 2021.    

If an extension to the Transition Period is agreed between the UK Government and EU, it is expected FMD will continue to apply in the UK for the duration of that extension period only.  

Under the Northern Ireland Protocol of the UK/EU Withdrawal Agreement the EU pharmaceutical regulatory framework will continue to apply in Northern Ireland.   This includes FMD and Delegated Regulation.  The UK industry stakeholders are working with EMVO to ensure a UKNI Medicines Verification System is in place and connected to EMVS by 01-Jan-2021 so that FMD can continue in the UK in respect of Northern Ireland.

We will communicate via our UK industry stakeholders and NCAs more detail on the UKNI MVS as the outcomes of the UK/ EU negotiations become clear from the UK government.

Related articles

Will Community/Hospital Pharmacies be able to return stock to their Wholesaler or a DTP manufacturer’s distributor?

This depends upon the terms and conditions of both the Wholesaler and the manufacturer. However, in general, we expect the current returns process will remain valid as long as the stock has not been decommissioned and the anti-tamper device is still intact.

First Login to UK MVS - Quick Start Guide - Step 1

Ready to log in to the UK MVS?  Please follow the links to instructions below.

Should we contact SecurMed to infiliate to GS1?

No. Please contact GS1 directly.

Does Article 37(d) require that a National Medicine Verification Organisation (NMVO) directly alerts the relevant national competent authorities, the EMA and the Commission about a falsification? Is there is a time limit for such alerting?

The use of the term “provide for” in Article 37(d) of Commission Delegated Regulation (EU) 2016/161 means that an NMVO has to ensure that the National Competent Authorities (NCA), the EMA and the Commission are informed.

Is Gibraltar in scope of the FMD implementation and what about British Crown Dependencies and British Overseas Territories?

MHRA have confirmed with the UK Foreign Office that the Crown Dependencies of Jersey and Guernsey (including the other Channel Islands) and the Isle of Man are included within the FMD implementation. Gibraltar and all other British Overseas Territories e. g.

Where can I find a copy of the Delegated Regulation?

You can find the Delegated Regulation here.